CARDIOXYL PHARMACEUTICALS
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.
CARDIOXYL PHARMACEUTICALS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
Chapel Hill, North Carolina, United States
Country:
United States
Website Url:
http://www.cardioxyl.com
Total Employee:
10001+
Status:
Active
Contact:
+119198698586
Email Addresses:
[email protected]
Total Funding:
66.5 M USD
Technology used in webpage:
SPF Google Font API Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS GStatic Google Static Content Google Maps API Level 3 Communications
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
The Aurora Funds
The Aurora Funds investment in Series B - Cardioxyl Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series B - Cardioxyl Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series B - Cardioxyl Pharmaceuticals
OrbiMed
OrbiMed investment in Series B - Cardioxyl Pharmaceuticals
The Aurora Funds
The Aurora Funds investment in Venture Round - Cardioxyl Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Venture Round - Cardioxyl Pharmaceuticals
The Aurora Funds
The Aurora Funds investment in Series A - Cardioxyl Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series A - Cardioxyl Pharmaceuticals
Official Site Inspections
http://www.cardioxyl.com
- Host name: 165.89.235.20
- IP address: 165.89.235.20
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "Cardioxyl Pharmaceuticals" on Search Engine
Cardioxyl Pharmaceuticals - Crunchbase Company Profile
Company Type For Profit. Contact Email [email protected]. Phone Number +119198698586. Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel …See details»
Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.
Partnering News. Gains full rights to Cardioxyl’s novel nitroxyl (HNO) donor in Phase 2 development for acute decompensated heart failure. Strengthens Bristol-Myers Squibb’s pipeline and strategic focus on heart failure. Bristol-Myers Squibb Company (NYSE:BMY) and Cardioxyl Pharmaceuticals, Inc. announced today that the companies have ...See details»
Bristol-Myers bets $2B on Cardioxyl's heart failure therapy
Nov 2, 2015 Bristol-Myers Squibb ($BMY) is acquiring private biotech Cardioxyl Pharmaceuticals in a deal that could be worth more than $2 billion, bringing in a Phase II treatment for heart failure.See details»
Bristol-Myers to Acquire Cardioxyl, Focus on Heart Failure
Nov 3, 2015 The company has signed a definitive agreement to acquire Cardioxyl Pharmaceuticals, Inc. Through this acquisition, Bristol-Myers will gain complete rights to CXL-1427, the lead candidate at...See details»
Bristol-Myers to buy US biotechnology firm Cardioxyl for $2.07bn
Nov 3, 2015 Read more. The biotech firm is focused on the discovery and development of new therapeutic agents for treatment of cardiovascular disease. The acquisition is scheduled to be closed in the fourth quarter of this year, and will give BMS the rights to Cardioxyl’s new nitroxyl (HNO) donor (prodrug), CXL-1427.See details»
Cardioxyl Pharmaceuticals Announces Positive Results from First ...
CHAPEL HILL, N.C., Aug. 2 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular...See details»
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals
Nov 3, 2015 Bristol-Myers Squibb has announced that it is to acquire Cardioxyl Pharmaceuticals, a private biotechnology company focused on the discovery and development of novel therapeutic agents for the treatment of cardiovascular disease. The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl’s lead asset CXL-1427.See details»
Bristol-Myers Squibb Completes Previously Announced …
Dec 8, 2015 Partnering News. Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc. The transaction includes full rights to Cardioxyl’s lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug) in Phase 2 clinical development …See details»
Bristol-Myers Squibb to buy Cardioxyl for heart drug
Nov 2, 2015 Bristol-Myers Squibb (BMS) has agreed to buy US heart drug specialist Cardioxyl Pharmaceuticals for $300 million (£195 million) up front, plus up to $1.8 billion contingent on reaching development and regulatory milestones.See details»
Cardioxyl Sells to Bristol-Myers Squibb for up to $2 Billion - Cooley
Nov 5, 2015 Cardioxyl, based in Chapel Hill, North Carolina, is a privately-held, clinical stage biopharmaceutical company focused on the discovery and development of new classes of safe and effective therapies for the treatment of cardiovascular disease.See details»
Bristol-Myers Squibb Buys Cardioxyl Pharmaceuticals
May 13, 2016 The company, co-founded with David Kass and Nazareno Paolocci of the School of Medicine, was purchased for $300 million, and the total value could exceed $2 billion depending on future development and sales of CXL-1427, an intravenous treatment for acute decompensated heart failure.See details»
Cardioxyl Pharmaceuticals completes first clinical trial for heart ...
29th July 2014. 1404. Cardioxyl Pharmaceuticals has announced the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers.See details»
Cardioxyl Pharmaceuticals, Inc. - Dun & Bradstreet
Overview. Company Description: Key Principal: Christopher A Kroeger See more contacts. Industry: Pharmaceutical and Medicine Manufacturing , Chemical Manufacturing , Manufacturing , Druggists' preparations (pharmaceuticals)See details»
Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.
Nov 2, 2015 Biotech. Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc. Nov 2, 2015 10:07am. Gains full rights to Cardioxyl's novel nitroxyl (HNO) donor in Phase 2 development for acute...See details»
Christopher A. Kroeger - President and CEO @ Cardioxyl Pharmaceuticals ...
Overview. CB Rank (Person) 365,694. Primary Job Title President and CEO. Primary Organization. Cardioxyl Pharmaceuticals. Gender Male. Dr. Christopher A. Kroeger was appointed President and Chief Executive Officer in 2008, having served on the company's Board of Directors since 2006.See details»
Cardioxyl Pharmaceuticals - Funding, Financials, Valuation
Funding. Cardioxyl Pharmaceuticals has raised a total of. $66.5M. in funding over 4 rounds. Their latest funding was raised on Nov 13, 2012 from a Series B round. Cardioxyl Pharmaceuticals is funded by 4 investors. The Aurora Funds and New Enterprise Associates are the most recent investors. Unlock for free. Funding Rounds.See details»
Evotec achieves milestone with Cardioxyl Pharmaceuticals - as …
Hamburg, Germany/ Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC), a leading provider in the discovery and development of novel small molecule drugs, today announced that the company has achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that …See details»
Cardioxyl begins Phase I study of CXL-1427 for heart failure …
Feb 26, 2014 US-based Cardioxyl Pharmaceuticals has started dosing the first cohort of patients in a Phase I clinical study of CXL-1427, a new nitroxyl (HNO) prodrug optimised for clinical development as a potential treatment for acute decompensated heart failure (ADHF). admin February 26, 2014.See details»
Organization | Cardioxyl Pharmaceuticals - CDEK
Organization Overview. First Clinical Trial. 2009 NCT01092325. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Cardioxyl Pharmaceuticals, Inc Active Ingredients. Drugs in Phase 2 Trials (2) Cimlanod ...See details»
Research programme: nitroxyl-based cardiovascular therapeutics ...
Bristol-Myers Squibb (previously Cardioxyl Pharmaceuticals) is developing nitroxyl (HNO) donor therapeutics for the treatment of heart failure and other Research programme: nitroxyl-based cardiovascular therapeutics - Bristol-Myers Squibb - AdisInsightSee details»